A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Study of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAR9182
U.S. Govt. ID: NCT02974621
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to investigate a novel treatment regimen for patients with recurrent Glioblastomas (GBM). In this phase 2 trial, the potentially synergistic action of PARP inhibition and anti-angiogenesis on DNA repair and biomarkers of angiogenesis and DNA repair will be evaluated.
This study is closed
Investigator
Mary Welch, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have recurrent glioblastoma? Yes No
Is this the first or second time your glioblastoma reoccurred? Yes No
Did your first treatment include radiotherapy and temozolomide? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE